SHINE Technologies Completes Acquisition of Lantheus SPECT Business

Lantheus Acquires Life Molecular Imaging (Life Molecular) for $350M Upfront

July 22, 2025

Healthcare Services

Lantheus Holdings completed its previously announced acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd. The deal includes an upfront payment of $350 million and (per the earlier definitive agreement) up to $400 million in potential earn-out and milestone payments, and strengthens Lantheus’s commercial and R&D capabilities in Alzheimer’s PET diagnostics with Neuraceq (florbetaben F18).

Lantheus Holdings to Acquire Evergreen Theragnostics for $250 Million Upfront

January 28, 2025

Healthcare Services

Lantheus Holdings has signed a definitive agreement to acquire Evergreen Theragnostics in an all-cash deal with a $250 million upfront payment and up to $752.5 million in development and sales milestones. The acquisition is intended to expand Lantheus into a fully integrated radiopharmaceutical leader by adding Evergreen’s radiopharmaceutical CDMO manufacturing infrastructure and development capabilities, as well as the registrational-stage PET diagnostic agent OCTEVY.

Bruker Corporation Acquires Spectral Instruments Imaging

February 6, 2024

Medical Devices

Bruker Corporation has acquired Spectral Instruments Imaging LLC, a Tucson-based maker of preclinical in‑vivo optical imaging systems, to broaden Bruker BioSpin's preclinical imaging portfolio. Financial terms were not disclosed; SII generated over $10 million in revenue in 2023 and will expand Bruker's capabilities in bioluminescence, fluorescence and X‑ray preclinical imaging.

Lantheus Holdings Acquires Cerveau Technologies

February 6, 2023

Pharmaceuticals

Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.

Dynatrace Acquires SpectX

September 14, 2021

Data & Analytics

Dynatrace has completed the acquisition of high-speed parsing and query analytics company SpectX to enhance observability and application security analytics within its Software Intelligence Platform. The deal brings SpectX's parsing/query analytics technology and team into Dynatrace to accelerate the convergence of observability and security for hybrid, multicloud environments.

Lantheus Acquires Meilleur Technologies (NAV-4694)

July 15, 2024

Pharmaceuticals

Lantheus Holdings, Inc. announced the acquisition of Meilleur Technologies, Inc., giving Lantheus worldwide exclusive rights to NAV-4694 (F18-flutafuranol), a Phase 3 ß-amyloid PET imaging agent for Alzheimer’s disease. The deal includes an upfront payment plus potential development/commercial milestones and royalties, and the sellers will provide transition and clinical development services following closing.